Cytokinetics (NASDAQ:CYTK) Reaches New 52-Week Low - Time to Sell?

Key Points

• Cytokinetics shares hit a 52-week low, trading as low as $57.55 and last at $56.60, down from the prior close of $63.60.
• Q3 results beat expectations: the company reported a $1.37-per-share loss versus the $1.43 estimate, while revenue of $47.56 million topped forecasts and rose sharply year over year. However, Cytokinetics remains unprofitable.
• Analyst sentiment is broadly positive, with a “Moderate Buy” consensus and an average price target of $105.44; aficamten and adoption of MYQORZO are cited as potential growth drivers.

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) shares hit a new 52-week low during trading on Thursday. The company traded as low as $57.55 and last traded at $56.60, with a volume of 575,260 shares trading hands. The stock had previously closed at $63.60.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Q3 results topped expectations. Cytokinetics reported a loss of $1.37 per share, narrower than the $1.43 analyst estimate and $2.55 loss a year earlier. Revenue of $47.56 million beat the $41.88 million consensus and rose sharply year over year, supporting the view that the business is progressing. Cytokinetics Q3 Loss Narrows, Revenue Rises
• Positive Sentiment: Aficamten and MYQORZO could provide further growth drivers. Recent coverage highlights aficamten data and the potential effect of MYQORZO adoption, which investors may view as important to the company’s commercial outlook. A separate valuation article argues CYTK could be 41% undervalued, though that is an estimate rather than a guaranteed return. Valuation and aficamten article MYQORZO adoption article
• Negative Sentiment: Losses continue. Despite the year-over-year improvement and earnings beat, Cytokinetics still reported a quarterly net loss, so investors will look for sustained revenue growth and progress toward profitability. Q3 loss and revenue estimates
• Neutral Sentiment: Insider sale was under a pre-arranged plan. EVP Fady Malik sold 3,500 shares, about 2.22% of his holdings, but the transaction was conducted under a Rule 10b5-1 plan, which makes it a less direct signal about near-term business prospects. Insider sale report

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Cytokinetics in a research note on Thursday, October 15th. William Blair initiated coverage on Cytokinetics in a research report on Friday, October 16th. They issued an "outperform" rating on the stock. Truist Financial increased their target price on Cytokinetics from $106.00 to $112.00 and gave the company a "buy" rating in a research note on Monday, August 10th. Royal Bank Of Canada raised their price target on shares of Cytokinetics from $112.00 to $113.00 and gave the stock an "outperform" rating in a research report on Thursday, October 8th. Finally, Needham & Company LLC raised their price target on shares of Cytokinetics from $102.00 to $112.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Nineteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Cytokinetics currently has a consensus rating of "Moderate Buy" and an average target price of $105.44.

Cytokinetics Price Performance

The firm has a market cap of $6.87 billion, a P/E ratio of -7.67 and a beta of 0.45. The firm's 50-day moving average price is $66.63 and its 200 day moving average price is $70.05.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) earnings per share for the quarter, beating the consensus estimate of ($1.43) by $0.06. The firm had revenue of $47.56 million during the quarter, compared to the consensus estimate of $41.88 million. During the same period in the prior year, the firm earned ($2.55) earnings per share. The firm's quarterly revenue was up 2356.5% compared to the same quarter last year. Analysts forecast that Cytokinetics, Incorporated will post -5.97 earnings per share for the current year.

Insider Transactions at Cytokinetics

In related news, Director B. Parshall sold 5,000 shares of the firm's stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $71.48, for a total transaction of $357,400.00. Following the transaction, the director directly owned 10,784 shares in the company, valued at $770,840.32. This trade represents a 31.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Fady Malik sold 3,500 shares of Cytokinetics stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $68.29, for a total transaction of $239,015.00. Following the completion of the transaction, the executive vice president directly owned 153,902 shares of the company's stock, valued at approximately $10,509,967.58. This represents a 2.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 180,926 shares of company stock worth $12,510,340 in the last quarter. Insiders own 2.60% of the company's stock.

Institutional Trading of Cytokinetics

Institutional investors and hedge funds have recently modified their holdings of the business. Pictet Asset Management Holding SA grew its stake in Cytokinetics by 18.4% during the 3rd quarter. Pictet Asset Management Holding SA now owns 1,374,523 shares of the biopharmaceutical company's stock worth $90,569,000 after buying an additional 214,060 shares during the last quarter. Principal Financial Group Inc. lifted its stake in shares of Cytokinetics by 11.9% in the 1st quarter. Principal Financial Group Inc. now owns 1,093,485 shares of the biopharmaceutical company's stock worth $72,072,000 after acquiring an additional 116,593 shares during the period. ADAR1 Capital Management LLC increased its stake in shares of Cytokinetics by 17.1% during the first quarter. ADAR1 Capital Management LLC now owns 632,556 shares of the biopharmaceutical company's stock valued at $41,692,000 after acquiring an additional 92,390 shares during the period. Candriam S.C.A. raised its holdings in Cytokinetics by 39.3% during the third quarter. Candriam S.C.A. now owns 617,386 shares of the biopharmaceutical company's stock worth $40,841,000 after purchasing an additional 174,320 shares in the last quarter. Finally, Siren L.L.C. bought a new stake in Cytokinetics during the first quarter worth approximately $40,466,000.

About Cytokinetics

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.